Group: Board of Directors

John Taylor

John is Co-Founder, President and CEO of Aceragen, leading the effort to acquire     ACG-801 and the funding to support its development.  He has extensive experience in the orphan and rare disease field, having spent a significant portion of his career developing therapeutic products in this area. Prior to Aceragen, John co-founded and was

Ron Wooten

As founding Managing Partner, Mr. Wooten has extensive healthcare and investing experience. His responsibilities include NovaQuest Capital’s overall oversight, investment policy, investor relations, and the day-to-day management of NovaQuest Capital and its investment platform. He is also a member of the Private Equity and Product Finance investment committees. Over a ten-year period during which NovaQuest

Stephen Lesser

As Vice President, Mr. Lesser has extensive experience advising companies in dynamic and heavily regulated environments on complex transactions, including corporate finance, venture capital and M&A, commercial operations, governance, regulatory, and general corporate matters.  He is responsible for providing general legal advice, and structuring, negotiating, and monitoring investment opportunities. Before joining NovaQuest, Mr. Lesser spent

Atul Chopra

Atul is a Physician-Scientist and Medical Geneticist specializing in rare genetic disorders of metabolism and energy balance. These disorders typically have a genetic cause such as a single gene mutation or a larger deletion/duplication affecting many genes together. An example of his work is the discovery of asprosin, a hormone that controls appetite and glucose

Dan Salain

Dan has 28 years of global pharmaceutical experience in manufacturing, supply chain management, strategic sourcing, distribution, quality, operations and business development. During his career, he participated in the successful launch and introduction of over 30 global products including Zenpep®, Lamictal®, Amrix®, Canasa® and Metadate CD®. Prior to joining Aceragen, he served as COO at Greybug

Andy Jordan

My career started in public accounting where I rose to the level of partner at KPMG. Having worked with many entrepreneurs, I sought to do the same and left KPMG in 1993 to help start Guilford Pharmaceuticals, a biotech company located in Baltimore, MD. At Guilford, I helped take Guilford through an IPO and over

Stay Connected

Join our newsletter & stay updated with all the news and events